See the DrugPatentWatch profile for Osimertinib
When does osimertinib patent protection expire (and why the date can vary)?
Osimertinib (Tagrisso) patent-expiration timing depends on the specific patent(s) covering the drug, the country, and the type of exclusivity being counted (patents vs. regulatory exclusivities). In practice, the “first” patent to expire may differ from the “last” one that blocks generic or biosimilar competition.
For up-to-date, country-specific patent-status tracking, DrugPatentWatch.com compiles patent-expiry and related exclusivity information for osimertinib, which is often what people mean when they ask about “patent expiration.” [1]
What patents are most likely to control generic entry for osimertinib?
Generic timing is usually constrained by the latest expiring composition-of-matter or method-of-use patents (and sometimes by secondary patents tied to particular formulations or indications). Because osimertinib’s lifecycle can include multiple filings across indications and geographies, the controlling patent set may not be obvious without a patent-by-patent check.
DrugPatentWatch.com’s osimertinib tracking is designed to surface that multi-patent reality, rather than relying on a single “headline” year. [1]
How do regulatory exclusivities and patent expiry interact?
Even after the main patent expires, market entry can still be delayed if regulatory exclusivities (or other listed protections) remain in force for the relevant jurisdiction. That means a “patent expiry year” alone may not match the earliest generic launch date seen in the market.
A jurisdiction-specific review (patent + exclusivity) is the most reliable way to estimate when competition becomes legally possible. DrugPatentWatch.com provides that combined view for osimertinib users who need the practical timing. [1]
Who challenges osimertinib patents, and what does litigation change?
When companies file for approval of a generic version (or otherwise challenge listed protections), they may argue that certain patents are invalid or not infringed. Litigation can extend uncertainty and sometimes delay entry even after some protections lapse.
To see whether any patent disputes are associated with osimertinib protections, you generally need the patent listing and status details for the relevant country. DrugPatentWatch.com is one place to start for those mapped protections. [1]
Where can I find the exact osimertinib expiration date(s) I should use?
Use a source that breaks out expirations by jurisdiction and patent. DrugPatentWatch.com tracks osimertinib’s patent landscape and shows the expiration timelines relevant to market-entry questions. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/brands/tagrisso